Novartis wraps first phase of Alcon buyout

Novartis completed the first stage of its $38 billion takeover of the U.S. eye care company Alcon, paying Nestle $10.4 billion in cash for a 25 percent stake in the company, some $200 million less than the originally announced price. Novartis retains exclusive rights to buy Nestle's remaining 52 percent share. Report

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.